

FEB 14 2007



FOLEY & LARDNER LLP
ATTORNEYS AT LAW
1530 PAGE MILL ROAD
PALO ALTO, CALIFORNIA 94304-1125
TELEPHONE: 650.856.3700
FACSIMILE: 650.856.3710
WWW.FOLEY.COM

FACSIMILE TRANSMISSION

Total # of Pages : 4 (including this page)

TO:	PHONE #:	FAX #:
Examiner Misook Yu United States Patent And Trademark Office		571.273.8300

From :	Karen E. Flick
Date :	14 February 2007
Applicant:	Anthony E. Bolton et al.
U.S. Patent Application No.:	09/866,488
Client/Matter No :	355908-1650

MESSAGE:

Enclosed:

Letter Requesting Acknowledgement
PTO-Form 1449 Information Disclosure Citation submitted 20 January 2004

If there are any problems with this transmission or if you have not
received all of the pages, please call .

Operator: D. Jones-Beasley	Time Sent:	Return Original To: Karen E. Flick
-------------------------------	------------	---------------------------------------

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

Cover Page 1 of 1

FOLEY & LARDNER LLP

SVCA 51710.1

FEB 14 2007

Atty. Dkt. No. 355908-1650

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony E. BOLTON et al.

Title: APOPTOTIC ENTITIES FOR
USE IN TREATMENT OF T-
CELL-MEDIATED AND
INFLAMMATORY
DISORDERS

Appl. No.: 09/866,488

Filing Date: 5/25/2001

Examiner: Misook Yu

Art Unit: 1642

Confirmation 4401
Number:

CERTIFICATE OF FACSIMILE TRANSMISSION I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office, Alexandria, Virginia (Fax No. 571-273-8300) on the date below. _____ Deborah Beasley (Printed Name) _____ (Signature) 14 February 2007 (Date of Deposit)
--

LETTER REQUESTING ACKNOWLEDGEMENT

Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In reviewing the above-captioned application file upon Allowance, the undersigned has noted that Applicants' PTO-Form 1449 submitted with their Disclosure Statement on 20 January 2004, has not been acknowledged by the Patent and Trademark Office.

SVCA_51788.1

The Patent and Trademark Office is, therefore, requested to return the initialed form to the undersigned as soon as possible.

Respectfully submitted,

Date 14 February 2007

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 251-1115
Facsimile: (650) 856-3710


By Karen E. Flick

Karen E. Flick
Attorney for Applicant
Registration No. 44,111

SVCA_51788.1

FEB 14 2007

Sheet 1 of 1

PTO Form 1449		ATTY DOCKET NO. 55908-20018.00	APPLICATION NO 09/866,488
 <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>		APPLICANT Anthony E. BOLTON, et al.	
		FILING DATE May 25, 2001	GROUP 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

1.	ADORINI, L. "Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases," <i>CMLS Cell. Mol. Life. Sci.</i> 55: 1610-1625 (1999).
2.	DE FOUGEROLLES, A.R., et al. "Regulation of inflammation by collagen-binding integrins $\alpha 4 \beta 1$ and $\alpha 2 \beta 1$ in models of hypersensitivity and arthritis," <i>The Journal of Clinical Investigation</i> 106(6): 721-729 (2000).
3.	PARK, S., et al. "Shift Toward T Helper 1 Cytokines by Type II Collagen-Reactive T Cells in Patients with Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> 44(3): 569-569 (2001).
4.	PEEVA, E., et al. "Rheumatoid Arthritis Exacerbation Caused by Exogenous Interleukin 12," <i>Arthritis & Rheumatism</i> 42(2): 461-463 (2000).
5.	PERLMAN, H., et al. "IL-6 Matrix Metalloproteinase-1 Are Regulated by the Cyclin-Dependent Kinase Inhibitor p21 in Synovial Fibroblasts," <i>The Journal of Immunology</i> 170: 838-845 (2003).
6.	SPADARO, A., et al. "Il ruolo dell'Interleuchina-12 nelle malattie reumatiche a patogenesi immunitaria," <i>Reumatismo</i> 54(2): 113-121 (2002). ABSTRACT IN ENGLISH
7.	TAYLOR, P.C. "Anti-TNF α Therapy for Rheumatoid Arthritis: an Update," <i>Internal Medicine</i> 42(1): 15-20 (2003).

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.